ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics

por Drooger, J.C, Dees, A, Swaak, A.J.G
Publicado 2009

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer

por Buijs, S.M., Hoop, E. Oomen-de, Braal, C.L., van Rosmalen, M.M., Drooger, J.C., van Rossum-Schornagel, Q.C., Vastbinder, M.B., Koolen, S.L.W., Jager, A., Mathijssen, R.H.J.
Publicado 2023

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

por Bouwer, N. I., Steenbruggen, T. G., van Rosmalen, J., Rier, H. N., Kitzen, J. J. E. M., van Bekkum, M. L., Tije, A. J. Ten, de Jong, P. C., Drooger, J. C., Holterhues, C., Smorenburg, C. H., Kofflard, M. J. M., Boersma, E., Sonke, G. S., Levin, M.-D., Jager, A.
Publicado 2021